Medindia

X

Questcor to Present at the Cowen and Company 30th Annual Health Care Conference in Boston

Thursday, February 25, 2010 General News J E 4
Advertisement

UNION CITY, Calif., Feb. 25 /PRNewswire-FirstCall/ -- Questcor Pharmaceuticals, Inc. (Nasdaq: QCOR) announced today that it will present at the Cowen and Company 30th Annual Health Care Conference on Monday, March 8, 2010 at The Boston Marriott Copley Place in Boston, Massachusetts. Don M. Bailey, President and Chief Executive Officer, will discuss the Company's business strategy and historical financial performance at 2:30 p.m. Eastern Time.

Attendance at the conference is by invitation only. A live audio Webcast of Questcor's presentation may be accessed through the Company's website at www.questcor.com. An archived replay of the presentation will be available after the live presentation, and can also be accessed at www.questcor.com.

About Questcor

Questcor Pharmaceuticals, Inc. is a pharmaceutical company that markets H.P. Acthar® Gel (repository corticotropin injection). H.P. Acthar Gel ("Acthar") is an injectable drug that is approved for the treatment of certain disorders with an inflammatory component, including the treatment of exacerbations associated with multiple sclerosis ("MS") and to induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that is due to lupus erythamatosus. In addition, Acthar is not indicated for, but is used in treating patients with infantile spasms ("IS"), a rare form of refractory childhood epilepsy, and opsoclonus myoclonus syndrome, a rare autoimmune-related childhood neurological disorder. The Company also markets Doral® (quazepam), which is indicated for the treatment of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings. For more information, please visit www.questcor.com.

SOURCE Questcor Pharmaceuticals, Inc.

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Delcath Systems, Inc. to Participate at Upcoming I...
S
Mylan Reports Adjusted Diluted EPS of $0.33 for th...